Axsome Therapeutics Inc
Axsome Therapeutics Inc (AXSM) Wheel Strategy
AXSM wheel strategy scan found 72 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 581.3%.
Read more
Running a AXSM wheel strategy lets you generate consistent premium income on Axsome Therapeutics Inc while setting your own entry and exit prices on the underlying. Axsome Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own AXSM, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best AXSM wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on AXSM, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable AXSM wheel from a losing one.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the AXSM wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your AXSM wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Nov 20, 2026 | 135.00 | $0.50 | $2.15 | -0.45 | 1 | 81% | 57.6% | 581.3% | 160 |
| Dec 18, 2026 | 130.00 | $3.50 | $4.95 | -0.35 | 29 | 81% | 58.6% | 47.9% | 29 |
| Jan 15, 2027 | 130.00 | $6.50 | $8.50 | -0.37 | 57 | 81% | 54.6% | 41.9% | 701 |
| Dec 18, 2026 | 125.00 | $2.00 | $3.95 | -0.27 | 29 | 81% | 68.1% | 39.8% | 66 |
| Jan 15, 2027 | 125.00 | $4.50 | $6.60 | -0.30 | 57 | 81% | 61.6% | 33.8% | 117 |
| Mar 19, 2027 | 130.00 | $11.00 | $13.10 | -0.37 | 120 | 81% | 50.7% | 30.7% | 122 |
| Dec 18, 2026 | 120.00 | $1.05 | $2.88 | -0.20 | 29 | 81% | 76.8% | 30.2% | 17 |
| Jan 15, 2027 | 120.00 | $3.30 | $5.15 | -0.25 | 57 | 81% | 68.5% | 27.5% | 409 |
| Mar 19, 2027 | 125.00 | $8.80 | $10.85 | -0.32 | 120 | 81% | 55.6% | 26.4% | 0 |
| Dec 18, 2026 | 110.00 | $1.00 | $2.20 | -0.14 | 29 | 81% | 90.1% | 25.2% | 15 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →